U.S. Markets open in 3 hrs 37 mins
  • Gold

    1,787.70
    +2.80 (+0.16%)
     
  • EUR/USD

    1.1648
    -0.0004 (-0.0349%)
     
  • 10-Yr Bond

    1.6360
    0.0000 (0.00%)
     
  • Vix

    16.02
    +0.32 (+2.04%)
     
  • GBP/USD

    1.3801
    -0.0025 (-0.1808%)
     
  • USD/JPY

    114.0300
    -0.2990 (-0.2615%)
     
  • BTC-USD

    66,319.70
    +2,387.99 (+3.74%)
     
  • CMC Crypto 200

    1,566.96
    +86.16 (+5.82%)
     
  • FTSE 100

    7,202.47
    -20.63 (-0.29%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

Aspen eyes Serum Institute model as it seeks licence to make J&J vaccine

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

JOHANNESBURG, Sept 2 (Reuters) - South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.

"At the moment, J&J could take all the product we make because it's their product, and sell it to Europe, for example, sell it to the U.S. or Korea, wherever they choose to. We have no say in that," he told Reuters.

"It's like Serum where they get the licences to manufacture. It's not a foreign model and it's very exciting," he said on the licensing talks. (Reporting by Promit Mukherjee; Editing by Edmund Blair)